Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company known for its proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs). This strategic acquisition reinforces Johnson & Johnson's commitment to advancing precision biologics and transforming the treatment of cancers, including prostate cancer.